Leukemia ALL Relapse / Refractory
ALL Relapse / Refractory
Showing 11 - 14 of 14 records.
SNDX-5613-0707: Expanded Access Program for SNDX-5613
- Ages: 30 Days and older
This expanded access program will provide an investigational treatment option in a controlled clinical setting for patients who are not otherwise eligible to participate in a clinical study and have no approved treatment options. SNDX-5613-0707: Expanded Access Program for SNDX-5613 in Patients Wit ...More
Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients (CASSIOPEIA)
- Ages: 1 Year to 25 Years
This is a single arm, open-label, multi-center, phase II study to determine the efficacy and safety of tisagenlecleucel in de novo HR pediatric and young adult B-ALL patients who received first-line treatment and are EOC MRD positive. The study will have the following sequential phases: screening, p ...More
T2020-006: Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
- Ages: 1 Year to 21 Years
- Gender: Female, Male
Tagraxofusp is a protein-drug conjugate consisting of a diphtheria toxin redirected to target CD123 has been approved for treatment in pediatric and adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). This trial aims to examine the safety of this novel agent in pediatric patien ...More
Venetoclax Combined with Vyxeos for Relapsed/Refractory Acute Leukemia
- Ages: 1 Year to 39 Years
This study evaluates the safety and tolerability of combining venetoclax with Vyxeos (CPX-351) in pediatric and young adult patients with acute leukemia that has come back or no responded to treatment. This is a single-institution Phase I pilot study designed to test the safety and tolerability of c ...More
Contact Us
To learn more about available leukemia clinical trials, contact us at cancer@cchmc.org or 513-636-2799.
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026
© 1999-2024 Cincinnati Children's Hospital Medical Center. All rights reserved.
